Fatal Cholestatic Liver Injury during Treatment with PD1 Immune Checkpoint Inhibitor for Malignant Melanoma: A Case Report.

Abstract

The use of immune checkpoint inhibitors has dramatically improved the chance of surviving malignant melanomas; however, the effect comes at the cost of toxicities that are difficult to predict. Immune-mediated hepatitis is the most common form of liver toxicity, but fatal outcome is uncommon. We report the case of a 70-year-old female with metastatic malignant melanoma who developed severe liver toxicity characterized by bile duct injury and cholestasis. The condition progressed despite potent immunosuppressive treatment, plasmapheresis, and intensive supportive care; and the patient died while still having tumor response.

• Authors: Thuridur Thorsteinsdottir, Teje Løitegård, Henrik Mikael Reims, Alina Carmen Porojnicu
• Journal: Case reports in oncology (Case Rep Oncol) 2020 May-Aug Vol. 13 Issue 2 Pg. 659-663 ISSN: 1662-6575 [Print] Switzerland
• PMID: 32774252 (Publication Type: Case Reports)
• Copyright: Copyright © 2020 by S. Karger AG, Basel.